# A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET

> **NCT04427787** · PHASE2 · UNKNOWN · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 69 (estimated)

## Conditions studied

- Metastatic Well Differentiated Neuroendocrine Neoplasm
- Neuroendocrine Tumors

## Interventions

- **DRUG:** Cabozantinib
- **DRUG:** Lanreotide

## Key facts

- **NCT ID:** NCT04427787
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-20
- **Primary completion:** 2023-11
- **Final completion:** 2023-11
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2021-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04427787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04427787, "A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04427787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*